PACTR201804003188338Recruiting未知
A Randomized, 28-days, Parallel-group, Equivalence Study to Compare the Effectiveness of 10mg Fe2+ Spatone Iron-Plus and 60mg Fe2+ Ferrous sulphate in Improving Haemoglobin Status of Pregnant Women in Lagos University Teaching Hospital
Dr. George Obioma-Okorie0 sites200 target enrollmentStarted: March 13, 2018Last updated:
Trial Snapshot
- Phase
- 未知
- Status
- Recruiting
- Sponsor
- Enrollment
- 200
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Year(s) to 44 Year(s) (—)
- Sex
- Female
Inclusion Criteria
- •Subjects willing and able to give informed consent for participation in the trial
- •Pregnant women who have a singleton fetus
- •Aged 18 to 44 years
- •Gestational age between 14 and 27 weeks of pregnancy
Exclusion Criteria
- •Pregnant women with multifetal pregnancy
- •History of allergy to iron containing preparation
- •History of chronic medical conditions such as chronic renal failure, haemoglobinopathy
- •History of chronic inflammatory/infectious diseases such as tuberculosis or HIV infection in pregnancy
- •Inability to return for follow-up visit at 4 weeks after enrolment
- •Severe anaemia or anaemia with clinical features of cardiac failure
Investigators
Similar Trials
Not yet recruiting
Not Applicable
Effect of Albendazole in combination with Ivermectin in treatment of soil transmitted heminthiasisCTRI/2022/01/039738MANKIND PHARMA LTD
Active, not recruiting
Phase 3
Clinical trial to compare effects and safety of Lupins Ranibizumab with Lucentis�® in Patients with Age-Related loss of central vision.CTRI/2019/03/018322upin Limited Biotechnology Division
Active, not recruiting
Phase 1
A Randomized, Double-Blind, Parallel Group, Equivalence, Multicenter Phase III Trial to Compare the Efficacy and Safety of Fusidic Acid Hydrophilic Cream 20 mg/g and Fucidin® Cream in the Treatment of Adult and Pediatric Subjects with Impetigo.Impetigo contagiosaMedDRA version: 20.0Level: PTClassification code 10021531Term: ImpetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10041923Term: Staphylococcal impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: PTClassification code 10042178Term: Streptococcal impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10021535Term: Impetigo NOSSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10041939Term: Staphylococcus aureus impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.0Level: LLTClassification code 10042200Term: Streptococcus pyogenes impetigoSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 20.1Level: LLTClassification code 10021533Term: Impetigo contagiousSystem Organ Class: 10021881 - Infections and infestationsEUCTR2020-002219-24-BEBasic Pharma Technologies200
Active, not recruiting
Phase 1
AN EQUIVALENCE TRIAL TO COMPARE THE EFFICACY, SAFETY, PHARMACOKINETICS AND IMMUNOGENICITY OF HD204 TO AVASTIN® IN PATIENTS WITH LUNG CANCER.on-squamous Non-small Cell Lung Cancer (nsNSCLC)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 100000004864EUCTR2017-005175-78-LVPrestige BioPharma Limited592
Active, not recruiting
Phase 1
AN EQUIVALENCE TRIAL TO COMPARE THE EFFICACY, SAFETY, PHARMACOKINETICS AND IMMUNOGENICITY OF HD204 TO AVASTIN® IN PATIENTS WITH LUNG CANCER.EUCTR2017-005175-78-HUPrestige BioPharma Pte Ltd592